← Leaderboards
Manikkam Suthanthiran
Weill Medical College Of Cornell Univ
$17,019,909
Attributed
$18,768,700
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$18,768,700 · 9
By mechanism
R01$10,263,929 · 5
R37$4,668,188 · 1
UH3$2,509,396 · 1
UH2$988,187 · 1
R21$339,000 · 1
Top collaborators
- Thomas Tuschl5 shared
Others in their field
Top investigators on “Biopsy”
- David Heimbrook · Leidos Biomedical Research, Inc.$97,871,847
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ralph Parchment · Leidos Biomedical Research, Inc.$43,674,966
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Peter Scott Heeger · Case Western Reserve University$37,822,090
Research focus
BiopsyUrineUrinaryKidney TransplantationKidney AllograftClinical TrialsTransplantationKidneyCellsDiagnosticMessenger RnaSpecimenAcuteBaseEnrollmentGenesAllograftingOrgan TransplantationValidationChronic Rejection Of Renal TransplantMicrornasAtrophicDiagnostic TestsCohort Studies
Grant awards (40)
Biomolecular Markers for Safe Minimization of Immunosuppression$374,941
R37 · FY2021 · AI · contact PI
Biomolecular Markers for Safe Minimization of Immunosuppression$402,247
R37 · FY2018 · AI · contact PI
Clinical utility of extracellular RNA as marker of kidney disease progression$835,118
UH3 · FY2017 · TR
Biomolecular Markers for Safe Minimization of Immunosuppression$407,822
R37 · FY2017 · AI · contact PI
Clinical utility of extracellular RNA as marker of kidney disease progression$835,584
UH3 · FY2016 · TR
Biomolecular Markers for Safe Minimization of Immunosuppression$582,734
R37 · FY2016 · AI · contact PI
Clinical utility of extracellular RNA as marker of kidney disease progression$838,694
UH3 · FY2015 · TR
Biomolecular Markers for Safe Minimization of Immunosuppression$418,489
R37 · FY2015 · AI · contact PI
Clinical utility of extracellular RNA as marker of kidney disease progression$488,188
UH2 · FY2014 · TR
Biomolecular Markers for Safe Minimization of Immunosuppression$423,748
R37 · FY2014 · AI · contact PI
Clinical utility of extracellular RNA as marker of kidney disease progression$499,999
UH2 · FY2013 · TR
Biomolecular Markers for Safe Minimization of Immunosuppression$389,248
R37 · FY2013 · AI · contact PI
Biomolecular Markers for Safe Minimization of Immunosuppression$414,092
R37 · FY2012 · AI · contact PI
FoxP3 Regulatory Network mRNA Profiles and Human Renal Transplant Outcomes$563,423
R01 · FY2011 · AI · contact PI
Biomolecular Markers for Safe Minimization of Immunosuppression$414,092
R37 · FY2011 · AI · contact PI
FoxP3 Regulatory Network mRNA Profiles and Human Renal Transplant Outcomes$569,094
R01 · FY2010 · AI · contact PI
Biomolecular Markers for Safe Minimization of Immunosuppression$418,275
R37 · FY2010 · AI · contact PI
FoxP3 Regulatory Network mRNA Profiles and Human Renal Transplant Outcomes$558,101
R01 · FY2009 · AI · contact PI
FoxP3 Regulatory Network mRNA Profiles and Human Renal Transplant Outcomes$535,857
R01 · FY2009 · AI · contact PI
Biomolecular Markers for Safe Minimization of Immunosuppression$422,500
R37 · FY2009 · AI · contact PI
FoxP3 Regulatory Network mRNA Profiles and Human Renal Transplant Outcomes$541,846
R01 · FY2008 · AI · contact PI
Noninvasive diagnosis of BKV nephropathy$351,604
R01 · FY2008 · AI · contact PI
FoxP3 Regulatory Network mRNA Profiles and Human Renal Transplant Outcomes$553,253
R01 · FY2007 · AI · contact PI
Noninvasive diagnosis of BKV nephropathy$358,413
R01 · FY2007 · AI · contact PI
Urine mRNA Profiling for Renal Allograft Surveillance$413,792
R01 · FY2006 · AI · contact PI
Noninvasive diagnosis of BKV nephropathy$369,118
R01 · FY2006 · AI · contact PI
Urine mRNA Profiling for Renal Allograft Surveillance$423,750
R01 · FY2005 · AI
Noninvasive diagnosis of BKV nephropathy$378,000
R01 · FY2005 · AI
Urine mRNA Profiling for Renal Allograft Surveillance$423,750
R01 · FY2004 · AI
Noninvasive diagnosis of BKV nephropathy$378,000
R01 · FY2004 · AI
Urine mRNA Profiling for Renal Allograft Surveillance$423,750
R01 · FY2003 · AI
TGF-BETA1 AND EXCESS RENAL DISEASE IN AFRICAN AMERICANS$660,890
R01 · FY2002 · DK
Urine mRNA Profiling for Renal Allograft Surveillance$625,875
R01 · FY2002 · AI
CYCLOSPORINE, TGF BETA1, AND IMMUNOSUPPRESSION$298,693
R01 · FY2002 · AI
Gene Therapy for Islet Cell Transplantation$169,500
R21 · FY2002 · DK
TGF-BETA1 AND EXCESS RENAL DISEASE IN AFRICAN AMERICANS$641,639
R01 · FY2001 · DK
CYCLOSPORINE, TGF BETA1, AND IMMUNOSUPPRESSION$289,993
R01 · FY2001 · AI
Gene Therapy for Islet Cell Transplantation$169,500
R21 · FY2001 · DK
TGF-BETA1 AND EXCESS RENAL DISEASE IN AFRICAN AMERICANS$623,541
R01 · FY2000 · DK
CYCLOSPORINE, TGF BETA1, AND IMMUNOSUPPRESSION$281,547
R01 · FY2000 · AI